Market Access

An industry-based working group presents a common standards and definition framework for “Access” competencies in pharma-as a starting point in solving the current shortage of talent and leaders for this widening set of activities.

The surprise victory of Donald Trump opens the door to new strategies for providing healthcare to Americans, including coverage and oversight of prescription drugs.

Pharm Exec sits down with Anthony Marucci, co-founder and CEO of Celldex, a stealth player in the immunotherapy field.

A new industry working group explores alternative drug funding options in Europe-and asks key stakeholders in the region to join the discussion.

William Looney speaks with DIA's Global Chief Executive to see how the organization is repositioning itself as the go-to place for the independent insights in a business with no boundaries.

Whatever used to be wrong with the world of big Pharma could be fixed with a single tag phrase: emerging country markets. Most of the majors have invested heavily in this geographic segment, and the biggest of the big-companies like Novartis-now rely on it for more than a quarter of their global sales. Like all good things, however, there are shadows amidst the sunlight, and the task of turning volume sales into sustainable profits is getting harder.

Pharm Exec talks with David Dosa, a leading physician in geriatric medicine, whose famous work with a cat named oscar in end-of-life diagnostics became the stuff of therapeutic legend.

As vital contributors to hospital disaster preparedness, the pharma industry has a role to play in making sure medical networks have what they need to meet the unforeseen, including future disasters.

In the past few years, we’ve seen the biopharmaceutical industry begin to shift from a one-size-fits-all blockbuster approach toward an individualized, precision science model. This transformation has propelled companion diagnostics (CDx) into playing a more critical role than ever in the commercialization of biopharmaceutical therapeutics.

A new and more compelling strategy must be crafted to engage critics on drug pricing and bolster biopharmaceuticals as a leader in technological innovations that lower health costs overall.

A response to the therapeutic potential of using bacteriophages as antibiotics - though doubtful phages can be applied as antibiotics have, they do offer mighty weapons against threats of antibiotic resistance.

Ed Schoonveld highlights the wait confronting lung cancer patients seeking Opdivo in the UK. Can we find room for compromise?

A non-antibiotic bactericidal treatment for humans was first proven effective in 1919. Ansis Helmanis asks why they are not commercially available in the United States.

Commercial success for pharma brands now demands proactive strategies and interventions

Susan Crowley reviews the hotly debated agenda items from last month's World Health Assembly (WHA) in Geneva, Switzerland.

NICE's proposed Innovation Office emerges with a new name. Leela Barham reports.

What’s new in the growing field of global market access?

Positive early stage trial results for Biogen’s aducanumab has renewed hope for effective solutions for Alzheimer's Disease, but many challenges remain in finding and funding new treatment, writes Ed Schoonveld.

As more new products vie for payer and prescriber attention, the stakes around launch success are higher than ever. Stan Bernard outlines the key traps to avoid in getting things right - when it really counts.

I offered up a prediction: that the future of the biopharmaceutical business depended on how managers fared on five key measures of performance.

Andrea Sobrio and Dr. Sandra Schoenes examine the market access challenges and opportunities specifically for premium, specialty inpatient products in the LatAm region.

The growing clamor for broader access to information on health care practices, policies and costs is affecting research, marketing and compliance, writes Jill Wechsler.

Pharm Exec convenes a diverse panel of experts to identify the key markers of common ground: its time, people, and money against that greatest intangible-hope.

Real-world pharmacoeconomic data can provide critical insight for maximizing US market access and oncology product differentiation, and should be central to the overall brand strategy of any oncology product

Patient access is the new driver of change and progress in healthcare marketing, says a senior industry player in market development.